UC – Urothelial carcinoma
Introduction
Since the introduction of PD-L1 as a biomarker for therapy with checkpoint inhibitors in non-small-cell lung carcinomas (NSCLC), further studies have been held on the correlation between expression of PD-L1 and carcinomas of other primary localizations. With a view to the urothelial carcinomas, not only the expression on the tumor cells, but also on the immune cells has been examined. As a function of the outcomes of these studies, registrations have already been given for various medications with varying scores and cut-offs.
Data protection and the German Drug Advertising Act (HWG) require that the professional affiliation of the portal visitors. The complete page with all contents is only available to medical personnel.
You can login with DocCheck, you QuIP-Account or Access-Code.
Login with QuIP-Account
Please enter your user name (e-mail address) and the corresponding password, which you also need for your login to the ring trial portal www.quip.eu can be used.
Login with Access-Code
Please enter your personal code, which you have already received by voucher.